# Partial Splenic Embolization in a Patient with Hemophilia A and Severe Thrombocytopenia: A Case Report

## TL;DR

A patient with hemophilia A and severe low platelet count successfully underwent a minimally invasive procedure to improve his quality of life.

## Contribution

This case report demonstrates the effectiveness of partial splenic embolization in managing thrombocytopenia in a hemophilia A patient with multiple viral infections.

## Key findings

- Partial splenic embolization increased platelet counts and improved quality of life in a hemophilia A patient.
- The procedure allowed the patient to safely undergo HCV treatment without serious complications.
- Long-term stability was achieved without major infections or platelet count relapses.

## Abstract

We report a patient with hemophilia A who underwent partial splenic embolization (PSE) for severe thrombocytopenia secondary to portal hypertension-induced splenomegaly, resulting in a stable long-term quality of life. The patient was diagnosed with hemophilia A and unfortunately contracted human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) from blood products. He subsequently developed progressive splenomegaly due to portal hypertension from chronic HCV, resulting in severe thrombocytopenia. PSE was performed because he had occasional subcutaneous bleeding and needed to start interferon (IFN) and ribavirin (RBV) treatment for curing his HCV infection at that time. His platelet counts increased, and no serious adverse events were observed. Currently, he continues to receive outpatient treatment, regular factor VIII (FVIII) replacement therapy for hemophilia A, and antiretroviral therapy for HIV infection. Vascular embolization has been reported to be an effective and minimally invasive treatment for bleeding in hemophilia patients. PSE also provided him with a stable quality of life without the side effects of serious infections and thrombocytopenia relapses. We conclude that PSE is a promising therapeutic option for patients with hemophilia A.